Transforming the Lives of Patients Through Precision Radiopharmaceuticals

There is no denying the targeted radiopharmaceuticals (TRP) sector is gaining significant momentum and shows no signs of slowing. AtomVie Global Radiopharma and TerraPower Isotopes recently announced a strategic supply agreement for Actinium-225 to support the development and manufacturing of TRP therapeutics. This follows a $1.3 billion licensing deal for OncoACP3 and a new Gadolinium-160 supply partnership between ASP Isotopes and Isotopia.

These milestones underscore the rapid advancement of precision radiopharmaceuticals: validated tumor-targeting therapies are entering clinical stages, isotope supply chain collaborations are strengthening, and the global TRP market is projected to triple by 2031.

As demand surges, the opportunity to shape the future of precision oncology and nuclear medicine has never been greater. However, key challenges remain, ranging from R&D and clinical translation to manufacturing scale-up and regulatory navigation.

The 4th Targeted Radiopharmaceuticals Summit US returned to San Diego, uniting 275+ global stakeholders from biotech, pharma, and academia, to tackle these challenges head on. Leading organizations including Novartis, AstraZeneca, Bristol Myers Squibb, Ratio Therapeutics, Alpha-9 Oncology, AdvanCell, Mariana Oncology, and Abdera Therapeutics all committed to advancing their pipeline and registered their place.

As the industry’s premier end-to-end platform, the summit was solely dedicated to accelerating the development and delivery of next-generation TRP therapeutics to capitalize on the potential of nuclear medicine. Across 3 days jam-packed with content across three focused tracks, we explored cutting-edge targeting molecules, enhancing clinical translational success, and overcoming isotope supply constraints.